Showing results (21-30 of 206) with videos related to

Sort By:
Pageof 21
Expert Opinion on Investigational Drugs|October 22, 2002
Therapeutic developments in the treatment of amyotrophic lateral sclerosisMandy Jackson, Jerònia Lladó, Jeffrey D Rothstein
Movement Disorders : Official Journal of the Movement Disorder Society|September 13, 2014
Preclinical models: needed in translation? A Pro/Con debateThomas Philips, Jeffrey D Rothstein, Mahmoud A Pouladi
Trends in Neurosciences|June 15, 2014
Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studiesSteve Vucic, Jeffrey D Rothstein, Matthew C Kiernan
Biorxiv : the Preprint Server for Biology|January 3, 2024
Highly variable molecular signatures of TDP-43 loss of function are associated with nuclear pore complex injury in a population study of sporadic ALS patient iPSNsJeffrey D Rothstein, Caroline Warlick, Alyssa N Coyne
Trends in Cell Biology|August 31, 2013
Oligodendroglia: metabolic supporters of axonsBrett M Morrison, Youngjin Lee, Jeffrey D Rothstein
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 7, 2022
Nuclear Pore Dysfunction in NeurodegenerationOlivia Spead, Benjamin L Zaepfel, Jeffrey D Rothstein
Annals of Neurology|March 30, 2004
Altered expression of the glutamate transporter EAAT2b in neurological diseaseNicholas J Maragakis, Margaret Dykes-Hoberg, Jeffrey D Rothstein
Nature Reviews. Neuroscience|May 7, 2016
The expanding biology of the C9orf72 nucleotide repeat expansion in neurodegenerative diseaseAaron R Haeusler, Christopher J Donnelly, Jeffrey D Rothstein
Pageof 21